Relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: part 3, imatinib for chronic myeloid leukemia (CML)
Abernethy A P, McCrory D C
Record ID 32006000314
English
Authors' objectives:
The aim of this review is to report on the relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy, in particular on imatinib for chronic myeloid leukemia (CML).
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.ahrq.gov/clinic/ta/cml/
Year Published:
2005
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Antineoplastic Agents
- Pyrimidines
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.